Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
USA PATENT GRANTS FOR
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) announces the granting of
patent number 9,579,382 entitled Use of Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte Immune Response by the United States Patent Office.
The method of use claims granted for this patent will provide protection for the treatment of cancer where a plurality of doses of IMP321 is used to generate
a monocyte mediated response. Broad claims covering dosage and route of administration have also been granted. As part of the Company s intellectual property strategy, further applications have been filed in the US seeking additional protection
for the IMP321 product itself and for use in combination with other reagents. Patent expiry is expected to be 6 July 2029 after a patent term adjustment of 276 days.
Prima BioMed is a globally active
biotechnology company and a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to
Prima s current lead product is IMP321, based on the LAG-3 immune control mechanism which
plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase IIb clinical
trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT
02676869). A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners. Prima is also
developing an agonist of LAG-3 (IMP761) for autoimmune disease.
Prima BioMed is listed on the Australian
Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please
Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Australia Investor/Media:
Mr Matthew Gregorowski,
Citadel Communications
+61 2 8234 0100; mgregorowski@citadelmagnus.com
Prima BioMed Ltd, Level 12, 95 Pitt Street, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889